Basilea Pharmaceutica AG: Basileas Partner Asahi Kasei Pharma reicht Antrag auf Marktzulassung (NDA) von Isavuconazol in Japan ein

Ad hoc-Mitteilung gemäss Art. 53 KR Basel, 30. September 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) in Japan

Related Keywords

Germany ,Norway ,Australia ,Iceland ,United States ,Liechtenstein ,Canada ,Russia ,Switzerland ,Turkey ,America ,German ,Swiss ,Basilea ,Sher Corporation ,Services Or Achievements Of Basilea ,S Partnership ,Swiss Exchange ,Market Approval ,Hoc Notification ,Fungal Infections ,Milestone Payment ,For Approval ,Sales Markets ,Tee Payment ,Percent Range ,Product Sales ,End June ,Prior Year Period ,About Isavuconazole ,Member States ,Active Ingredient Orphan Drug Status ,Latin America ,Asia Pacific Space ,Near East ,North Africa ,About Basilea ,Cancer Or Infections ,Drug Candidates ,Areas Oncology ,Infectious Diseases ,Ticker Symbol ,Website Basilea ,Exclusion Clause This Message ,Her Business Activities ,Product Candidate ,Such Propositional ,Factors Of Uncertainty ,Services Or Achievements ,New Information ,Source Instructions ,Restricted Access ,Admission Status ,Notes Press Release ,Pharmaceutica ,Easileas ,Partner ,Asahi ,Kasei ,Dharma ,Leicht ,Intrag ,Marktzulassung ,Savuconazol ,Japan ,